



RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
MAR 14 2003

Patent
Attorney's Docket No. 032901-039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Samuel Weiss, et al.) Group Art Unit: 1614
Application No.: 10/084,671) Examiner: Unassigned
Filed: February 28, 2002) Confirmation No.: 2544
For: ESTROGEN INDUCED NEURAL STEM CELL)
INCREASE)
)

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a Supplemental Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

By: _____
Ping F. Hwung
Registration No. 44,164

Date: March 12, 2003



Attorney's Docket No. 05901039

TECH CENTER 1600/2900
RECEIVED
M A R 1 4 2 0 0 3
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Samuel Weiss et al.) Group Art Unit: 1614
Application No.: 10/084,671) Examiner: Unassigned
Filed: February 28, 2002) Confirmation No.: 2544
For: ESTROGEN INDUCED NEURAL STEM)
CELL INCREASE)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

1. International Publication WO 95/13364, published May 18, 1995.
2. International Publication WO 00/41700, published July 20, 2000.
3. Garcia-Segura, L.M., et al., "Neuroprotection by estradiol", *Progress in Neurobiology*, **63**:29-57 (2001).
4. Inestrosa, N.C., et al., "Cellular and Molecular Basis of Estrogen's Neuroprotection", *Molecular Neurobiology*, **17**:73-86 (1998).
5. Kawas, C., et al., "A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging", *Neurology*, **48**:1517-1521 (1997).
6. Nakafuku, M., et al., "Establishment and Characterization of a Multipotential Neural Cell Line That Can Conditionally Generate Neurons, Astrocytes, and Oligodendrocytes In Vitro", *J. of Neuroscience Research*, **41**:153-168 (1995).
7. Ohkura, T., et al., "Evaluation of Estrogen Treatment in Female Patients with Dementia of the Alzheimer Type", *Endocrine Journal*, **41**:361-271 (1994).

Supplemental Information Disclosure Statement
Application No. 10/084,671
Attorney's Docket No. 032901-039
Page 2


These documents are being submitted before a first Office Action on the merits, therefore no fee is required under 37 C.F.R. § 1.97(b). In the event an Office Action is mailed by the United States Patent and Trademark Office prior to receipt of this Information Disclosure Statement, the Patent Office is authorized to charge the appropriate fees to Deposit Account 02-4800.

By citing the above references, Applicants do not acquiesce or admit that any of these documents is "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Ping F. Hwung
Registration No. 44,164

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

Date: March 12, 2003



Substitute for form 1449A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.
032901-039

APPLICATION NO.
10/084,671

APPLICANT

FILING DATE
February 28, 2002

GROUP
1614

U.S. PATENT DOCUMENTS

Date of publication
(MM/DD/YYYY)
RECEIVED
MAR 14 2003
TECH CENTER 1800/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
	WO 95/13364		PCT	05/18/1995		
	WO 00/41700		PCT	07/20/2000		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Garcia-Segura, L.M., et al., "Neuroprotection by estradiol", <i>Progress in Neurobiology</i> , 63 :29-57 (2001).
	Inestrosa, N.C., et al., "Cellular and Molecular Basis of Estrogen's Neuroprotection", <i>Molecular Neurobiology</i> , 17 :73-86 (1998).
	Kawas, C., et al., "A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging", <i>Neurology</i> , 48 :1517-1521 (1997).
	Nakafuku, M., et al., "Establishment and Characterization of a Multipotential Neural Cell Line That Can Conditionally Generate Neurons, Astrocytes, and Oligodendrocytes In Vitro", <i>J. of Neuroscience Research</i> , 41 :153-168 (1995).
	Ohkura, T., et al., "Evaluation of Estrogen Treatment in Female Patients with Dementia of the Alzheimer Type", <i>Endocrine Journal</i> , 41 :361-271 (1994).
Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.